474430-64-3

Upstream product

• 2818-82-8 2-methyl-4,5-diphenyl-1H-imidazole 
• 474429-79-3 7-(2-Methyl-4,5-diphenyl-imidazol-1-yl)-heptanoic acid ethyl ester 
• 1070-89-9 sodium hexamethyldisilazane 
• 141-78-6 ethyl acetate 
• 74-88-4 methyl iodide 

Downstream Products

• 474430-67-6 2-methyl-7-(2-methyl-4,5-diphenyl-imidazol-1-yl)-heptanoic acid 

Relevant academic research and scientific papers

Novel inhibitors of fatty acid amide hydrolase

A class of bisarylimidazole derivatives are identified as potent inhibitors of the enzyme fatty acid amide hydrolase (FAAH). Compound 17 (IC50 = 2 nM) dose-dependently (0.1-10 mg/kg, iv) potentiates the effects of exogenous anandamide (1 mg/kg,

Bisarylimidazolyl fatty acid amide hydrolase inhibitors

The present invention relates to bisarylimidazolyl derivatives and pharmaceutical compositions comprising said compounds inhibiting fatty acid amide hydrolase and useful for the treatment of pain, particularly neuropathic pain, psychomotor disorder, hypertension, cardiovascular disease, eating disorder, nausea, AIDS-related complex, glaucoma, inflammation, psoriasis or multiple sclerosis, and other conditions the treatment of which can be effected by inhibiting fatty acid amide hydrolase.